Pharma News Intelligence July 28, 2020
There were only two major pharmaceutical merger and acquisition deals so far, but the potential for more activity is there, PwC reports.
A recent PwC insights analysis found that the pharmaceutical merger and acquisition activity saw a notable decline in the first half of 2020, but the potential for consolidation in specific sub-sectors remains high.
There were only two major deals in the first quarter of 2020, Qiagen and Thermo Fisher Scientific at $11.8 billion and Forty Seven and Gilead at a $5.0 billion value.
This number reflects a major decline from the second half of 2019, which saw four major deals during the last six months of the year, researchers explained.
The difficulties in the global pharmaceutical and...
Today's Sponsors
Today's Sponsor